An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)

Trial Profile

An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Rintatolimod (Primary)
  • Indications Chronic fatigue syndrome; Encephalomyelitis
  • Focus Adverse reactions; Registrational
  • Sponsors Hemispherx Biopharma
  • Most Recent Events

    • 21 Jul 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
    • 21 Jul 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
    • 22 Apr 2016 Study design changed from parallel to single group and treatment arms changed from 3 to 1.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top